Oncodesign Services Acquires ZoBio; Eurazeo's Nov Santé Invests in Oncodesign

Edmond de Rothschild (ERES IV), Advised by Elyan Partners, Acquires Majority Stake in Oncodesign Services

July 1, 2022

Healthcare Services

Edmond de Rothschild Equity Strategies IV SLP (ERES IV), advised by Elyan Partners, acquired a majority stake in Oncodesign Services (ODS), taking control of a 61.58% block and announcing a planned simplified tender offer (OPAS) for the remaining shares. The transaction separates Oncodesign's Services and Biotech businesses and positions ODS for accelerated organic growth and potential bolt-on acquisitions under continued management involvement from founder Philippe Genne and CEO Fabrice Viviani.

Taconic Biosciences Acquires TransCure bioServices

January 20, 2026

Biotechnology

Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.

Servier Acquires Symphogen A/S from Novo Holdings and Other Owners

April 3, 2020

Biotechnology

Servier has acquired 100% of the share capital of Symphogen A/S from Novo Holdings and the remaining owners, taking ownership of the Danish therapeutic antibody discovery and early biologics development company. The deal brings Symphogen’s antibody discovery platform and CMC biologics development capabilities into Servier’s oncology and immuno-oncology R&D efforts to strengthen its biologics pipeline and development capacity.

Verdesian Life Sciences Acquires Cytozyme Laboratories

April 27, 2021

Agriculture

Verdesian Life Sciences has acquired Cytozyme Laboratories, Inc.; Cascadia Capital served as exclusive financial advisor to Cytozyme. The acquisition brings together complementary biological and nutritional crop technologies to expand Verdesian's product portfolio and support sustainable yield solutions for growers.

Eurofins Discovery Acquires DiscoveryBioMed

July 5, 2022

Biotechnology

Eurofins Discovery has acquired DiscoveryBioMed, a Birmingham, Alabama–based contract research organization specializing in human primary- and immortalized-cell based bioassays. The acquisition strengthens Eurofins Discovery’s translational biology and human cell assay capabilities to expand its drug discovery services portfolio.

AlphaRose Therapeutics Acquires Alpha Anomeric SA

April 29, 2025

Biotechnology

AlphaRose Therapeutics has acquired Alpha Anomeric SA, a Paris-based developer of the abcDNA oligonucleotide chemistry platform. The acquisition brings a proprietary antisense oligonucleotide chemistry into AlphaRose's portfolio and establishes a European presence to support global development of its neurogenetic and rare-disease programs. Terms were not disclosed.